Mar 13, 2009|
The time seems ripe for mergers
Mergers zoom in the global pharma space
The global pharma industry in the past few months has been on a consolidation overdrive. The biggest of the biggest deals took place when Pfizer announced that it was acquiring Wyeth for a staggering US$ 60 bn. Just a couple of days back, the US based company Merck acquired Schering Plough and yesterday, Roche was successful in buying out it the remaining stake in the biotech company Genentech. So what has compelled Big Pharma to go in for big ticket acquisitions especially when the global economy is in a downturn and credit is scarce? There are myriad reasons for these moves.
One is obviously the pipeline of drugs that the acquiring company will have access to. Thus, the acquisitions will not only enable Pfizer, Merck and Roche to augment their product portfolio and thereby minimize the risk of patent expiration of some of their existing drugs but will also enable them to have a presence in a new field. The latter especially holds true for Pfizer and Roche. By acquiring Wyeth, Pfizer can now boast of a presence in vaccines while Roche will have access to biotech drugs. The second reason is that global pharma companies have strong cash balances as a result of which they have been able to purchase companies even when the global economy is contracting and money is not readily available. But, while these acquisitions have sent out some signals that the health of the pharma industry is not overly affected, these companies will still have a tough task on their hands when it comes to digesting these purchases. At the end of the day, as is the case with any acquisition, successful integration is what will generate strong returns for shareholders.
India's 'inefficient' use of savings
While the global financial crisis has not spared even India in terms of slowdown in growth, the country is still better off than most of its developed peers, which have already plunged into recession. The fact that it is not as heavily reliant on exports as some of its Asian peers has also helped to a great extent. Add to this the fact that the Indian economy is not as overstretched as the Eastern European countries on foreign capital and it certainly seems that India is attracting the envy of many countries. As reported in the Economist, India's gross saving rate was around 38% of GDP in the past fiscal year. This speaks volumes of the country's prudence as compared to the US, where most Americans were heavily leveraged.
But as the magazine further goes on to add, India does not mobilize its savings well. It says, "Households account for almost two-thirds of it. But they put more than half of their spare funds into physical assets, such as homes, rather than the financial system. Of the remainder, 11% is held in cash and 55% is deposited in the banks, which are now lending almost a third of their deposits to the government." Maybe in some sense, that is a blessing in disguise. Leaving aside the fact that the financial crisis has firmly gripped every country in its clasp including India, it is precisely the latter's prudence which has prevented its banking system to fall prey to the ills that have plagued banks in the US and Europe. And the lower investment in the financial system means that India has more headroom to increase investments in this sector especially if they are used to haul up the country's considerably rickety infrastructure.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407